Flashback Foreword: Gemcitabine for Advanced Pancreatic Cancer

J Clin Oncol. 2023 Dec 20;41(36):5479-5480. doi: 10.1200/JCO.23.01895.

Authors

Eileen M O'Reilly^{1

2

3}, Andrew H Ko^{3

4}, Jonathan W Friedberg^{5

6

7}

Affiliations

¹ Memorial Sloan Kettering Cancer Center, New York, NY.
² Weill Cornell Medicine, New York, NY.
³ Associate Editor, Journal of Clinical Oncology, Alexandria, VA.
⁴ University of California San Francisco, San Francisco, CA.
⁵ Wilmot Cancer Institute, Rochester, NY.
⁶ University of Rochester, Rochester, NY.
⁷ Editor-in-Chief, Journal of Clinical Oncology, Alexandria, VA.

PMID: 38100990
PMCID: PMC10730035 (available on 2024-12-20)
DOI: 10.1200/JCO.23.01895

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Deoxycytidine / therapeutic use
Gemcitabine*
Humans
Pancreatic Neoplasms* / drug therapy

Substances

Gemcitabine
Deoxycytidine

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States